Hotgen Biotech has made a significant move in the biotech industry by acquiring Oriomics, a leading company in genomics and precision medicine. This strategic acquisition marks a major expansion of Hotgen's business.
Hotgen Biotech has been a key player in the biotech industry, with a strong focus on genomics and precision medicine. The acquisition of Oriomics adds a new dimension to Hotgen's capabilities.
With Oriomics on board, Hotgen Biotech now has access to cutting-edge genomics and precision medicine technologies. This will enable the company to offer more comprehensive solutions to its clients.
Hotgen Biotech's acquisition of Oriomics is a significant development in the biotech industry, and it's likely to have a lasting impact on the market.
You might enjoy: China National Salt Industry Corporation
Financials
Hotgen Biotech's financials are a mixed bag. In 2023, the company's net sales were $541M, but dropped to $511M in 2024.
Net income, on the other hand, was a loss of $191M in 2024, a significant decline from the $27.38M profit in 2023. The company's net debt also increased to $1.07B in 2024, up from -$587M in 2023.
Here's a breakdown of Hotgen Biotech's financials for 2023 and 2024:
Overall, Hotgen Biotech's financials suggest a challenging year in 2024, with declining net sales and a significant loss in net income.
Acquires 38.0993% of Oriomics for CNY 153 Million
Hotgen Biotech has made a significant move in the field of cancer screening by acquiring 38.0993% of Oriomics for CNY 153 million.
This acquisition is a major step in deepening Hotgen Biotech's layout in the field of early screening and diagnosis of liver cancer.
Valuation and Operations
Hotgen Biotech's valuation has been quite impressive, with a capitalization of 14.25B in one instance, and a P/E ratio of 132x in 2023.
Their enterprise value has fluctuated, ranging from 13.18B to 306B.
The company's free-float percentage is around 63.02%, which is a significant portion of the total capitalization.
In terms of yield, Hotgen Biotech had a yield of 0.49% in 2023, but unfortunately, there's no data available for 2024.
Here's a breakdown of some key valuation metrics for Hotgen Biotech:
Featured Images: pexels.com
